Head-to-head evidence
Mayzent vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
Mayzent
Marketed by Novartis
NCT03623243 · Phase 3 · completed
The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.
Ponesimod
Marketed by Vanda Pharmaceuticals
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mayzent's landscape · Ponesimod's landscape